Fri, Sep 26, 1:20 PM, Zacks
Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog
Currently, Myriad Genetics (MYGN) is financing 13 Phase III clinical trials with flagship product BracAnalysis CDx in six different indicated patient populations.
Wed, Sep 10, 1:00 PM, Zacks
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.